Last reviewed · How we verify

Compound lidocaine

Tianjin Medical University General Hospital · FDA-approved active Small molecule Under review Quality 0/100

Compound lidocaine is a Local anesthetic Small molecule drug developed by Tianjin Medical University General Hospital. It is currently FDA-approved for Local anesthesia for infiltration, nerve blocks, and topical application, Pain relief in minor surgical and dental procedures. Also known as: Compound Lidocaine Hydrochloride Injection.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Compound lidocaine is a small molecule that acts as a sodium channel alpha subunit blocker, classified as a blocker. It has been studied in various clinical trials for conditions such as knee osteoarthritis, vestibulodynia, temporomandibular disorder, fibromyalgia syndrome, and irritable bowel syndrome.

At a glance

Generic nameCompound lidocaine
Also known asCompound Lidocaine Hydrochloride Injection
SponsorTianjin Medical University General Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission along nerves. It is commonly used for infiltration anesthesia, nerve blocks, and topical anesthesia in clinical practice.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Compound lidocaine

What is Compound lidocaine?

Compound lidocaine is a Local anesthetic drug developed by Tianjin Medical University General Hospital, indicated for Local anesthesia for infiltration, nerve blocks, and topical application, Pain relief in minor surgical and dental procedures.

How does Compound lidocaine work?

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

What is Compound lidocaine used for?

Compound lidocaine is indicated for Local anesthesia for infiltration, nerve blocks, and topical application, Pain relief in minor surgical and dental procedures.

Who makes Compound lidocaine?

Compound lidocaine is developed and marketed by Tianjin Medical University General Hospital (see full Tianjin Medical University General Hospital pipeline at /company/tianjin-medical-university-general-hospital).

Is Compound lidocaine also known as anything else?

Compound lidocaine is also known as Compound Lidocaine Hydrochloride Injection.

What drug class is Compound lidocaine in?

Compound lidocaine belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Compound lidocaine in?

Compound lidocaine is FDA-approved (marketed).

What are the side effects of Compound lidocaine?

Common side effects of Compound lidocaine include Injection site reactions (pain, erythema), Systemic toxicity (tremor, dizziness, seizures) at high doses, Allergic reactions (rare with amide lidocaine), Methemoglobinemia (with topical spray formulations).

What does Compound lidocaine target?

Compound lidocaine targets Voltage-gated sodium channels and is a Local anesthetic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing